Annett Maderer
About
Annett Maderer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Annett Maderer has authored 25 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Annett Maderer's work include Colorectal Cancer Treatments and Studies (11 papers), Gastric Cancer Management and Outcomes (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Annett Maderer is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Gastric Cancer Management and Outcomes (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Annett Maderer collaborates with scholars based in Germany, United States and Belgium. Annett Maderer's co-authors include Markus Moehler, Peter R. Galle, Maurice Stephan Michel, Leonard Kaps, Wilfried Roth, Arno Schad, Peter Thuss‐Patience, Hauke Lang, Thomas Thomaidis and Florian Lordick and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Surgery.
In The Last Decade
Annett Maderer
24 papers receiving 435 citations
Peers
Annett Maderer
Daniele Lavacchi Italy
Francesco Catanzariti Italy
Defei Hong China
Chun‐Chieh Wu Taiwan
Diyu Huang China
Kateřina Kopečková Czechia
Domenico Germano Italy
Claire Gallois France
Masaki Tsujie Japan
E. Falcó Spain
Citations per year, relative to Annett Maderer Annett Maderer (= 1×)
peers
Daniele Lavacchi
Countries citing papers authored by Annett Maderer
Since
Specialization
Citations
This map shows the geographic impact of Annett Maderer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annett Maderer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annett Maderer more than expected).
Fields of papers citing papers by Annett Maderer
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Annett Maderer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annett Maderer. The network helps show where Annett Maderer may publish in the future.
Co-authorship network of co-authors of Annett Maderer
This figure shows the co-authorship network connecting the top 25 collaborators of Annett Maderer. A scholar is included among the top collaborators of Annett Maderer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annett Maderer. Annett Maderer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kaps, Leonard, Markus Moehler, Stephan Grabbe, et al.. (2025). Collagen turnover biomarkers to predict outcome of patients with biliary cancer. BMC Gastroenterology. 25(1). 53–53.
2.
Maderer, Annett, Daniel‐Christoph Wagner, Mairéad G. McNamara, et al.. (2025). 320P First-line therapy (1L) of cisplatin/gemcitabine (CisGem) with pembrolizumab (pembro) in patients with advanced biliary tract cancer (aBTC): Open-label, single-arm phase II EORTC-1607-GITCG/ABC-09 intergroup study with translational research (TR). Annals of Oncology. 36. S124–S125.
3.
Antwi, Samuel O., Shiho Arima, Julia Driscoll, et al.. (2022). Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. Frontiers in Oncology. 12. 963753–963753.
4.
Foersch, Sebastian, Monika Hartmann, Annett Maderer, et al.. (2021). Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients. Scientific Reports. 11(1). 16745–16745.
5.
Rades, Dirk, Tobias Bartscht, Peter Hunold, et al.. (2020). Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2). Strahlentherapie und Onkologie. 196(9). 795–804.
6.
Moehler, Markus, Annett Maderer, Peter Thuss‐Patience, et al.. (2020). Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). Annals of Oncology. 31(2). 228–235.
7.
Moore, Assaf, Tal Goshen‐Lago, Sara Morgenstern, et al.. (2020). Young-onset gastric cancer and Epstein–Barr Virus (EBV) – a major player in the pathogenesis?. BMC Cancer. 20(1). 34–34.
8.
Moehler, Markus, Annett Maderer, Friedrich Foerster, et al.. (2019). Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer. 19(1). 55–55.
9.
Lang, Hauke, J. Baumgart, Stefan Heinrich, et al.. (2019). Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases. Annals of Surgery. 270(5). 799–805.
10.
Moehler, Markus, Gunnar Folprecht, Volker Heinemann, et al.. (2019). Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. Journal of Clinical Oncology. 37(4_suppl). 571–571.
11.
Moehler, Markus, Gunnar Folprecht, Volker Heinemann, et al.. (2019). Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).. Journal of Clinical Oncology. 37(15_suppl). e15025–e15025.
12.
Desuki, Alexander, Frank Staib, Ines Gockel, et al.. (2019). Loss ofLLGL1Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. Canadian Journal of Gastroenterology and Hepatology. 2019. 1–12.
13.
Moehler, Markus, Arno Schad, Annett Maderer, et al.. (2018). Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071). Cancer Chemotherapy and Pharmacology. 82(4). 733–739.
14.
Stahl, M., Annett Maderer, Florian Lordick, et al.. (2018). Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). European Journal of Cancer. 93. 119–126.
15.
Nagel, Michael, Julia Schulz, Annett Maderer, et al.. (2018). Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial. Tumor Biology. 40(3). 3726238000–3726238000.
16.
Rades, Dirk, Annett Maderer, Peter Hunold, et al.. (2017). Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer. Anticancer Research. 37(5). 2703–2708.
17.
Maderer, Annett, et al.. (2014). Moguntinones—New Selective Inhibitors for the Treatment of Human Colorectal Cancer. Molecular Cancer Therapeutics. 13(6). 1399–1409.
18.
Thomaidis, Thomas, Annett Maderer, Salah‐Eddin Al‐Batran, et al.. (2014). VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer. 14(1). 476–476.
19.
Moehler, Markus, Thomas Thomaidis, Jens U. Marquardt, et al.. (2014). Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. Journal of Cancer Research and Clinical Oncology. 141(3). 515–522.
20.
Wehler, Thomas, Annett Maderer, Claudine Graf, et al.. (2012). Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy. International Journal of Colorectal Disease. 28(3). 385–398.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Daniele Lavacchi Breakdown of academic impact, for papers by Francesco Catanzariti Breakdown of academic impact, for papers by Defei Hong Breakdown of academic impact, for papers by Chun‐Chieh Wu Breakdown of academic impact, for papers by Diyu Huang Breakdown of academic impact, for papers by Kateřina Kopečková Breakdown of academic impact, for papers by Domenico Germano Breakdown of academic impact, for papers by Claire Gallois Breakdown of academic impact, for papers by Masaki Tsujie Breakdown of academic impact, for papers by E. Falcó